This Is MS Multiple Sclerosis Knowledge & Support Community

I have been reading the link many times, and cannot see that the abstract states how the dosage was given to the mice. I assume it was not oral.

It would be better if it were a muscular injection rather than a jab in the brain.

Sometimes I think I would like to come back as a mouse, but then I would be cured and not be able to get out of my cage and walk all over anyway. We can't win.

gwa

Hi GWA,
The article mentions "injection" multiple times but doesn't mention where.

They do mention testing blood serum concentrations within a matter of minutes, but not where the samples were taken from.

Gut feeling is that it would involve an injection but not in the brain. Then again, gut feelings and $2.00 might get you a coffee and a newspaper!

Despite the fact that it involves mice, I do like the fact that it is a human antibody being used. Somehow that seems to bring us a little closer to something which could make it through testing in humans while showing safety and effaciacy (sorry, brain block and I can't remember how to spell it!)
Bob

gwa wrote:Sometimes I think I would like to come back as a mouse, but then I would be cured and not be able to get out of my cage and walk all over anyway. We can't win.

I'd be more worried by the fact that tests for neurogenesis usually involve freezing and chopping off the mouses head. Thats one way stop the MS disease process.

CureOrBust wrote:

gwa wrote:Sometimes I think I would like to come back as a mouse, but then I would be cured and not be able to get out of my cage and walk all over anyway. We can't win.

I'd be more worried by the fact that tests for neurogenesis usually involve freezing and chopping off the mouses head. Thats one way stop the MS disease process.

HEY!! Now THAT'S got to be a fate worse than swallowing cute little baby parasites!!

Bob

I am very encouraged by rHIgM22. It's not even toxic, I want to try it today. Anything to reduce the effects of short circuiting wiring.
Avonex rocks (5 days a week), well I haven't accquired any new stuff in over 2 years for it. The two together I reckon is the basis of a real management for this thing.
Also, read Nov 2007 issue of scientific american, I also believe Vitamin D or the lack of it has a big part to play in MS. We need tannning beds in our therapy centres. Vtamin D activates about 1000 genes, largely regulatory mechanisms including cytokine regulation, which is the big problem in MS.

Who am I, no-one much, but I have MS and I understand the bioichem etc pretty thoroughly and I was right about beta interferon in 1993! I have a good intuitive feeling about rHIgM22 too.

bwmbagus wrote:I am very encouraged by rHIgM22. It's not even toxic, I want to try it today. Anything to reduce the effects of short circuiting wiring.
Avonex rocks (5 days a week), well I haven't accquired any new stuff in over 2 years for it. The two together I reckon is the basis of a real management for this thing.
Also, read Nov 2007 issue of scientific american, I also believe Vitamin D or the lack of it has a big part to play in MS. We need tannning beds in our therapy centres. Vtamin D activates about 1000 genes, largely regulatory mechanisms including cytokine regulation, which is the big problem in MS.

Who am I, no-one much, but I have MS and I understand the bioichem etc pretty thoroughly and I was right about beta interferon in 1993! I have a good intuitive feeling about rHIgM22 too.

Just to pick up on this, the article in the SciAm is really excellent, and covers a whole lot more than MS alone. The authors believe that the current RDA of Vitamin D is far too low. Reading between the lines of what they're saying, for people who live in high latitudes in N. Europe or N. America then at least 1000 IU of D3 would be a more realistic RDA than the current value of 400 IU.

Bit of an update on this drug.

Minnesota partnership advances potential MS therapy

Clinical-stage manufacturing progressing at Biovest in Minneapolis

ROCHESTER/MINNEAPOLIS, Minn. — A production laboratory founded by the Minnesota Partnership has transferred its first potential therapy — a medication for multiple sclerosis — to a processing plant in Minnesota. This step will complete purification of material to fully enable translation from preclinical to clinical development.

The antibody known as rHIgM22, developed at Mayo Clinic, was produced and purified in the Biotherapeutic Protein Production Laboratory created by a Partnership infrastructure award in 2006. This laboratory was developed within the Molecular and Cellular Therapeutics Facility on the St. Paul campus of the University of Minnesota. The therapy is under license to Acorda Therapeutics, Inc. (NASDAQ: ACOR), which is supporting the development of this potential therapy. This includes the Minnesota Partnership’s transfer of remaining production and purification to Biovest, Inc., in Minneapolis.